Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-010989
Filing Date
2019-11-14
Accepted
2019-11-14 08:01:22
Documents
59
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ettx-20190930x10q.htm 10-Q 1689444
2 EX-31.1 ettx-20190930ex311826b18.htm EX-31.1 15464
3 EX-31.2 ettx-20190930ex312767a0b.htm EX-31.2 14512
4 EX-32.1 ettx-20190930ex32181cad5.htm EX-32.1 9978
  Complete submission text file 0001558370-19-010989.txt   5403611

Data Files

Seq Description Document Type Size
5 EX-101.INS ettx-20190930.xml EX-101.INS 970840
6 EX-101.SCH ettx-20190930.xsd EX-101.SCH 46309
7 EX-101.CAL ettx-20190930_cal.xml EX-101.CAL 49884
8 EX-101.DEF ettx-20190930_def.xml EX-101.DEF 164237
9 EX-101.LAB ettx-20190930_lab.xml EX-101.LAB 404891
10 EX-101.PRE ettx-20190930_pre.xml EX-101.PRE 284209
Mailing Address 35 GATEHOUSE DRIVE WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE WALTHAM MA 02451 (781) 810-0120
Entasis Therapeutics Holdings Inc. (Filer) CIK: 0001724344 (see all company filings)

EIN.: 824592913 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38670 | Film No.: 191216389
SIC: 2834 Pharmaceutical Preparations